WO2004000322A1 - Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis - Google Patents

Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis Download PDF

Info

Publication number
WO2004000322A1
WO2004000322A1 PCT/EP2003/006601 EP0306601W WO2004000322A1 WO 2004000322 A1 WO2004000322 A1 WO 2004000322A1 EP 0306601 W EP0306601 W EP 0306601W WO 2004000322 A1 WO2004000322 A1 WO 2004000322A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
group
alkyl
oxygen
Prior art date
Application number
PCT/EP2003/006601
Other languages
French (fr)
Inventor
Bernard Gaudilliere
Henry Jacobelli
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Priority to AU2003246574A priority Critical patent/AU2003246574A1/en
Priority to MXPA05000004A priority patent/MXPA05000004A/en
Priority to BR0312107-0A priority patent/BR0312107A/en
Priority to CA002491210A priority patent/CA2491210A1/en
Priority to EP03760686A priority patent/EP1539176A1/en
Priority to JP2004514844A priority patent/JP2005538965A/en
Publication of WO2004000322A1 publication Critical patent/WO2004000322A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems

Definitions

  • the present invention relates to novel thiazine and oxazine derivatives which are useful for preparing medicinal products for treating complaints involving a therapy with a matrix metalloprotease-13 (MMP-13) inhibitor.
  • MMP-13 matrix metalloprotease-13
  • These medicinal products are useful in particular for treating certain inflammatory conditions such as rheumatoid arthritis or osteoarthritis, as well as certain proliferative conditions such as cancers.
  • MMPs Matrix metalloproteases
  • TMPs tissue inhibitors of metallopro tease
  • MMP-13 matrix metalloprotease-13 is a collagenase-type MMP which constitutes the predominant collagenase observed during osteoarthritis, in the course of which pathology the chondrocyte directs the destruction of cartilage.
  • MMP inhibitors are known. Most of these MMP-inhibitors are not selective for a single MMP, such as those described by Montana and Baxter (2000) or by Clark et al. (2000).
  • the applicant has identified novel thiazine and oxazine derivatives that are matrix metalloprotease inhibitors, and more specifically compounds that are selective MMP-13 inhibitors.
  • Xi, X 2 , and X 3 independently of each other, represent a nitrogen atom or a group -CR 3 in which R 3 represents a group selected from hydrogen, (C]-C 6 )alkyl, amino, mono(C ⁇ -C 6 )alkylamino, di(C ⁇ -C 6 )alkylamino, hydroxy, (C ⁇ -C 6 )alkoxy, and halogen, it being understood that not more than two of the groups X ⁇ , X 2 and X 3 simultaneously represent a nitrogen atom,
  • Gi represents an oxygen atom or a group S(O) p in which p represents an integer from 0 to 2 inclusive,
  • Yi represents a group selected from oxygen, sulphur, -NH and -N(C ⁇ -C 6 )alkyl
  • Y 2 represents a group selected from oxygen, sulphur, -NH and -N(C ⁇ -C 6 )alkyl
  • n represents an integer from 0 to 6 inclusive
  • hydrocarbon chain Z ⁇ optionally contains one to two isolated or conjugated multiple bonds
  • one of said -C jRs may be replaced with a group selected from oxygen, S(O) r in which r represents an integer from 0 to 2 inclusive, -NH and -N(C ⁇ -C 6 )alkyl,
  • hydrocarbon chain Z 2 optionally contains one or two isolated or conjugated multiple bonds
  • one of said -CR R]o may be replaced with a group selected from oxygen, S(O) u in which u is an integer from 0 to 2 inclusive, -NH, -N(C ⁇ -C 6 )alkyl, and carbonyl,
  • ⁇ / B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
  • - X 4 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by a hydrogen or a (C ⁇ -C 6 )alkyl group,
  • - k is an integer from 0 to 3 inclusive
  • - kl is an integer from 0 to 2 inclusive
  • - k2 is an integer from 1 to 4 inclusive
  • R ⁇ , R12 and R i3 which may be identical or different independently of each other, are selected from hydrogen and (C 1 -C 6 )alkyl,
  • R ⁇ 5 represents a (C 3 -C 6 )cycloalkyl group
  • - X 5 represents a group selected from a single bond, -CH 2 -, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C,-C 6 )alkyl,
  • R 2 which may be identical or different independently of each other, is (are) selected from (C ⁇ -C 6 )alkyl, halogen, -CN, -NO 2 , -SCF 3 , -CF 3 , -OCF 3 , -NR 7 R 8 , -OR 7 ,
  • X represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C ⁇ -C 6 )alkyl,
  • - k is an integer from 0 to 3 inclusive
  • L 5 - R 7 and R 8 which may be identical or different independently of each other, are selected from hydrogen and (d-C 6 )alkyl,
  • - X 8 represents a group selected from single bond, -CH 2 -, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C C 6 )alkyl,
  • JO - R ⁇ 8 represents a group selected from phenyl, a 5- or 6-membered monocyclic, heteroaryl, and a 5- or 6-membered monocyclic cycloalkyl, each of these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (C ⁇ -C 6 )alkyl, halogen, hydroxy and amino, and optionally, their racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts, and with the proviso that the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H- 1 ,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-l ,3-benzothiazine, 6- benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-l ,3
  • the invention relates to compounds of formula (I) wherein : • Gi represents a sulphur atom,
  • G 2 represents a group of formula (i/a):
  • Yj represents an oxygen atom
  • Y 2 represents a group -NH, • X ⁇ , X2, X , n, Zj, A, Re m and R2 are as defined in formula (I).
  • the invention relates to compounds of formula (I) wherein :
  • G 2 represents a group of formula (i/a):
  • the invention relates to compounds of formula (I) wherein :
  • n represents an integer from 1 to 6 inclusive
  • Xi, X 2 , X 3 , Zi, A, R ⁇ ; m and R2 are as defined in formula (I).
  • the invention relates to compounds of formula (I) wherein :
  • n represents an integer from 1 to 6 inclusive
  • Xi, X 2 , X 3 , Zi, A, Ri, m and R 2 are as defined in formula (I).
  • substituent Ri that is preferred according to the invention is the group of formula (i b):
  • Z2 represents a group -CR R ⁇ 0 in which R 9 and Rio represents each a hydrogen atom, s is equal to one, and B, G 3 , and t are as defined in the compound of formula (I).
  • substituent Ri that is preferred according to the invention is the group of formula (i/b):
  • B represents a phenyl group
  • t is equal to 0 or 1
  • Preferred compounds of the invention are compounds of formula (I) wherein X 1; X 2 , and X represent each a group -CR 3 in which R represents a hydrogen atom.
  • X ⁇ represents a group -CR 3 in which R 3 represents a hydrogen atom
  • X 2 represents a nitrogen atom
  • X 3 represents a group -CR 3 in which R 3 represents a hydrogen atom
  • preferred compounds of the invention are those compounds of formula (I) wherein Zi represents -CR 4 R 5 in which t and R 5 represent each a hydrogen atom, and n is equal to one.
  • Especially preferred compounds of the invention are compounds of formula (I) wherein A represents a phenyl group , m is equal to zero or one, and R 2 represents a (C]-C 6 )alkoxy group or a hydrogen atom.
  • preferred compounds of the invention are compounds of formula (I) wherein A represents a pyridyl group, m is equal to zero or one, and R 2 represents a (C ⁇ -C 6 )alkoxy group or a hydrogen atom.
  • Another especially preferred compounds of the invention are compound of formula (I) wherein A represents an imidazolyl group.
  • the invention relates to the following compounds of formula (I) : - 3-benzyl-2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]thiazine-6-carboxylic acid 4-methoxy benzylamide;
  • the optical isomers, the N-oxides, as well as the addition salts with a pharmaceutically- acceptable acid or base, of the preferred compounds form an integral part of the invention.
  • the invention also relates to a pharmaceutical composition comprising as active ingredient an effective amount of a compound of formula (I) together with one or more pharmaceutically-acceptable excipients or carriers.
  • Another embodiment of the invention concerns the use of the compound of formula (I) for the preparation of a medicinal product intended for treating a disease involving therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease.
  • the invention also relates to a method for treating a living body afflicted with a disease involving a therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease, the said method comprising the administration of an effective amount of a compound of formula (I) to a patient in need thereof.
  • a preferred method of treatment according to this invention is treatment of a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration and cancers.
  • a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration and cancers.
  • a preferred method of treatment according to this invention is treatment of disease selected from arthritis, osteoarthritis and rheumatoid arthritis.
  • - a (C ⁇ -C ⁇ )alkyl group denotes a linear or branched group containing from 1 to 6 carbon atoms ;
  • example of such groups, without implying any limitation are methyl, ethyl, propyl, isopropyl, tert-butyl, neopentyl, hexyl, - a (C 2 -C 6 )alkenyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more double bonds ;
  • examples of such groups without implying any limitation are vinyl, allyl, 3-buten-l-yl, 2-methyl-buten-l-yl, hexenyl, a (C 2 -C 6 )alkynyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more triple bonds ;
  • examples of such groups without implying any limitation are ethyn
  • - a (C ⁇ -C 7 )acyl group denotes an alkyl group or an aryl group as defined above bound through a carbonyl group ; examples of such groups without implying any limitation are acetyl, ethylcarbonyl, benzoyl,
  • a multiple bond denotes double bond or triple bond
  • a halogen atom means fluoro, chloro, bromo or iodo
  • optical isomers refer to racemates, enantiomers and diastereoisomers.
  • the invention also relates to the pharmaceutically acceptable salts of the compounds of formula (I).
  • a review of the pharmaceutically acceptable salts will be found in J. Pharm.
  • Pharmaceutically acceptable acids mean non-toxic mineral or organic acids. Among those there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, nitric acid, citric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid, benzoic acid, toluenesulfonic acid, etc...
  • Pharmaceutically acceptable bases mean non-toxic mineral or organic bases. Among those, there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, calcium hydroxide, triethylamine, tert-butylamine, dibenzylethylenediamine, piperidine, pyrrolidine, benzylamine, quaternary ammonium hydroxides etc...
  • the invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II): in which Xj, X 2 , X 3 , and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO 2 alkyl,
  • compounds of formula (I a) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
  • the invention also relates to another process for the preparation of specific compounds of formula (I/a), which are a particular case of compounds of formula (I), which uses as starting material a compound of formula (11/ A): in which G ⁇ has the same definitions as the compound of formula (I),
  • compounds of formula (I/c) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically- acceptable acid or base, or into N-oxide thereof.
  • the invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
  • X 2 , X 3 , and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO 2 alkyl,
  • compounds of formula (I/b) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically- acceptable acid or base, or into N-oxide thereof.
  • R is hydrogen or (C ⁇ -C 6 )alkyl
  • R" is hydrogen or (C ⁇ -C 6 )alkyl
  • compounds of the invention that are present in the form of a mixture of diastereoisomers are isolated in a pure form by using conventional separation techniques such as chromatography.
  • compounds of formula (I) of the present invention are matrix metalloprotease inhibitors, and more particularly inhibitors of the enzyme MMP-13.
  • the use of the compounds of the present invention may be recommended for the treatment of any pathology in which destruction of extracellular matrix tissue occurs, and most particularly pathologies such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration and cancers.
  • pathologies such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration and cancers.
  • the present invention also relates to pharmaceutical compositions comprising as active ingredient at least one compound of formula (I), an isomer thereof, a N-oxide thereof, or an addition salt thereof with a pharmaceutically-acceptable acid or base, alone or in combination with one or more pharmaceutically-acceptable, inert, non-toxic excipients or carriers.
  • compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), per- or trans-cutaneous, intravaginal, rectal, nasal, perlingual, buccal, ocular or respiratory administration.
  • compositions according to the invention for parenteral injections especially include aqueous and non-aqueous sterile solutions, dispersions, suspension and emulsions, and also sterile powders for reconstituting injectable solutions or dispersions.
  • compositions according to the invention for oral administration in solid form especially include tablets or dragees, sublingual tablets, sachets, gelatin capsules and granules, for oral, nasal, buccal or ocular administration in liquid form, especially include emulsions, solutions, suspensions, drop, syrups and aerosols.
  • Pharmaceutical compositions for rectal or vaginal administration are preferably suppositories, and those for per- or trans-cutaneous administration especially include powders, aerosols, creams, ointment, gels and patches.
  • compositions mentioned hereinbefore illustrate the invention but do 5 not limit it in any way.
  • inert, non-toxic excipients or carriers there may be mentioned, by way of non-limiting example, diluents, solvents, preservatives, wetting agents, emulsifiers, dispersing agents, binders, swelling agents, disintegrating agents, retardants, lubricants, absorbents, suspending agents, colorants, aromatizing agents etc...
  • the useful dosage varies according to the age and weight of the patient, the administration route, the pharmaceutical composition used, the nature and severity of the disorder and the administration of any associated treatments.
  • the dosage ranges from 2 mg to 1 g per day in one or more administrations.
  • the compositions are prepared by methods that are common to those skilled in the art and generally comprise 0.5% to 60% by weight of active
  • the starting materials used are products that are known or that are prepared according to known operating procedures.
  • the various preparations yield synthetic intermediates that '.0 are useful in preparation of the compounds of the invention. Some of these intermediates are new compounds.
  • TOTU O-(ethoxycarbonyl)cyanomethylamino]-N-N-N'-N'-tetramethyl uronium fluoroborate
  • aluminium chloride (5.51 g, 41.3 mmol) was added in portions to a suspension of 3-benzyl-6-bromo-3,4-dihydro-benzothiazine-2,4-dione (intermediate A ; 2.4 g, 6.89 mmol) in benzene (50 ml) and the mixture obtained was heated at 50°C under stirring for 2 hours.
  • the inhibitory activity of the compounds of formula (I) according to the invention with respect to matrix metalloprotease-13 is evaluated by testing the ability of the compounds of the invention to inhibit the proteolysis of a peptide substrate with MMP- 13.
  • the peptide substrate used in the test is the following peptide: Ac-Pro-Leu-Gly-thioester-
  • the inhibitory activity of a compound of formula (I) according to the invention is expressed as the IC 50 value, which is the concentration of inhibitor for which an inhibition of 50%) of the activity of the matrix metalloprotease under consideration is observed.
  • reaction medium of 100 ⁇ l volume is prepared, containing: 50 mM of HEPES buffer, 10 mM of CaCl 2 and 1 mM of 5,5'-dithiobis-(2-nitrobenzoic acid)
  • the concentrations of inhibitors present in the test samples range from 100 ⁇ M to 0.5 nM.
  • the measurement of the proteolysis of the substrate peptide is monitored by measuring the absorbance at 405 nm using a spectrophotometer for reading microplates, at the laboratory temperature, the measurements being carried out continuously for 10 to 15 minutes.
  • the IC 50 values are calculated from a curve in which the percentage of the catalytic activity relative to the control is represented on the X-axis and the concentration of inhibitor is represented on the Y-axis.
  • the test described above for the inhibition of MMP-13 was also adapted and used to determine the ability of the compounds of formula (I) to inhibit the matrix metalloproteases MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14.
  • the results obtained show that the compounds according to the invention generally have IC 50 values for MMP-13 which are about 100 times lower than the IC 50 values for the same compounds with respect to the other matrix metalloproteases tested.
  • the IC 50 values on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP- 12 and MMP- 14 for the compound of Example 1 are respectively 30 ⁇ M, lOO ⁇ M, 18 ⁇ M, 30 ⁇ M, lOO ⁇ M, lOO ⁇ M, and lOO ⁇ M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A compound selected from those of formula (I): wherein: • X1, X2, and X3 represent nitrogen or -CR3 in which R3 represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, • Gl represents oxygen or S(O)p in which p is from 0 to 2, • G2 represents carbon-carbon triple bond, C=O, C=S, S(O)q in which q is from 0 to 2, or a group of formula (i/a): in which YI and Y2 are as defined in the description, • n is fromO to 6, Zl represents -CR4R5, wherein R4 and R5 are as defined in the description, • A represents 5- or 6-membered monocycle or bicycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, • RI represents hydrogen, alkyl, alkenyl, alkynyl, (these groups may be optionally substituted as defined in the description) or the group of formula (i/b): in which s, Z2, B, t and G3 are as defined in the description, and optionally, its optical isomers , N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease, for the treatment of i.a arthritis and cancer.

Description

TITLE OF THE INVENTION
THIAZINE AND OXAZINE DERIVATIVES AS MMP- 13 INHIBITORS FOR TREATING ARTHRITIS
FIELD OF THE INVENTION
The present invention relates to novel thiazine and oxazine derivatives which are useful for preparing medicinal products for treating complaints involving a therapy with a matrix metalloprotease-13 (MMP-13) inhibitor. These medicinal products are useful in particular for treating certain inflammatory conditions such as rheumatoid arthritis or osteoarthritis, as well as certain proliferative conditions such as cancers.
TECHNOLOGICAL BACKGROUND OF THE INVENTION
Matrix metalloproteases (MMPs) are enzymes which are involved in the renewal of extracellular matrix tissue, such as cartilage, tendons and joints. MMPs bring about the destruction of the extracellular matrix tissue, which is compensated for, in a non- pathological physiological state, by its simultaneous regeneration.
Under normal physiological conditions, the activity of these extremely aggressive peptidases is controlled by specialized proteins which inhibit MMPs, such as the tissue inhibitors of metallopro tease (TIMPs).
Local equilibrium of the activities of MMPs and of TIMPs is critical for the renewal of the extracellular matrix. Modifications of this equilibrium which result in an excess of active MMPs, relative to their inhibitor, induce a pathological destruction of cartilage, which is observed in particular in rheumatoid arthritis and in osteoarthritis.
In pathological situations, an irreversible degradation of articular cartilage takes place, as is the case in rheumatic diseases such as rheumatoid arthritis or osteoarthritis. In these pathologies, the cartilage degradation process predominates, leading to a destruction of the tissue and resulting in a loss of function. At least twenty different matrix metalloproteases have been identified to date and are subdivided into four groups, the collagenases, the gelatinases, the stromelysins and the membrane-type MMPs (MT-MMPs), respectively. Matrix metalloprotease-13 (MMP-13) is a collagenase-type MMP which constitutes the predominant collagenase observed during osteoarthritis, in the course of which pathology the chondrocyte directs the destruction of cartilage.
There is a need in the prior art for novel MMP inhibitors, more particularly for MMP-13 inhibitors, in order to prevent and/or correct the imbalance in the renewal of extracellular matrix tissue, such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPD), age-related macular degeneration (ARMD) and cancer. MMP-inhibitor compounds are known. Most of these MMP-inhibitors are not selective for a single MMP, such as those described by Montana and Baxter (2000) or by Clark et al. (2000).
There is also a need in the prior art for novel inhibitors that are active on matrix metalloprotease-13, in order to enrich the therapeutic arsenal that can be used for treating pathologies associated with the destruction of the extracellular matrix and with cancer.
SUMMARY OF THE INVENTION
The applicant has identified novel thiazine and oxazine derivatives that are matrix metalloprotease inhibitors, and more specifically compounds that are selective MMP-13 inhibitors.
More specifically, the present invention relates to compounds of formula (I) :
Figure imgf000004_0001
wherein:
• Xi, X2, and X3, independently of each other, represent a nitrogen atom or a group -CR3 in which R3 represents a group selected from hydrogen, (C]-C6)alkyl, amino, mono(Cι-C6)alkylamino, di(Cι-C6)alkylamino, hydroxy, (Cι-C6)alkoxy, and halogen, it being understood that not more than two of the groups X\, X2 and X3 simultaneously represent a nitrogen atom,
• Gi represents an oxygen atom or a group S(O)p in which p represents an integer from 0 to 2 inclusive,
• G2 represents a group selected from carbon-carbon triple bond, C=O, C=S, S(O)q in which q represents an integer from 0 to 2 inclusive, or a group of formula (i/a):
Figure imgf000005_0001
in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Yi represents a group selected from oxygen, sulphur, -NH and -N(Cι-C6)alkyl, and Y2 represents a group selected from oxygen, sulphur, -NH and -N(Cι-C6)alkyl,
• n represents an integer from 0 to 6 inclusive,
• Zi represents -CP R5, wherein R and R5; identical or different independently of each other, represent a group selected from hydrogen, (Cι-C6)alkyl, trihalogeno(Cι-C6)alkyl, halogen, amino, mono(Cι-C6)alkylamino, di(Cι-C6)alkylamino in which each alkyl moiety is identical or different, -ORβ, -SRό, and -C(=O)OR6, in which R is hydrogen atom or
(Cι-C6)alkyl, and
- wherein when n is greater than or equal to 2, the hydrocarbon chain Z\ optionally contains one to two isolated or conjugated multiple bonds,
- and/or wherein when n is greater than or equal to 2 one of said -C jRs may be replaced with a group selected from oxygen, S(O)r in which r represents an integer from 0 to 2 inclusive, -NH and -N(Cι-C6)alkyl,
• A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles, represents a group selected from : hydrogen, (C]-C6)alkyl, (C2-C6)alkenyl, (C2-Ce)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(Cι-C6)alkyl, cycloalkyl, -C(=O)NR7R8, -C(=O)OR7, OR7; and SR7, in which R7 and R8, which may be identical or different independently of each other, represent hydrogen or (d-C6)alkyl, and the group of formula (i/b) :
Figure imgf000006_0001
•S in which s is an integer from 0 to 8 inclusive,
■ Z2 represents -CR9Rι0 wherein R and Rio, identical or different independently of each other, represent a group selected from hydrogen, ( -C^alkyl, phenyl, trihalogeno(C1-C6)alkyl, halogen, amino, ORό, SRό and -C(=O)ORό in which R^ is as defined hereinbefore, and
- wherein when s is greater than or equal to 2, the hydrocarbon chain Z2 optionally contains one or two isolated or conjugated multiple bonds,
- and/or wherein when p is greater or equal to 2, one of said -CR R]o may be replaced with a group selected from oxygen, S(O)u in which u is an integer from 0 to 2 inclusive, -NH, -N(Cι-C6)alkyl, and carbonyl,
■/ B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
•/ t is an integer from 0 to 7 inclusive,
■f the group(s) G3, which may be identical or different independently of each other, is (are) selected from (C C6)alkyl, halogen, CN, NO2, CF3, OCF3, -(CH2)kNRπRi2, -N(R„)C(=O)R12, -N(Rn)C(=O)ORi2, -N(Rn)SO2R12, -N(SO2Rπ)2, -ORH, -S(O)klRn, -SO ^RπHCH^-NR^Rn, -(CH2)kSO2NR„R12,
Figure imgf000007_0001
Figure imgf000007_0002
-X5-R16, and
Figure imgf000007_0003
in which :
- X4 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by a hydrogen or a (Cι-C6)alkyl group,
- k is an integer from 0 to 3 inclusive,
- kl is an integer from 0 to 2 inclusive,
- k2 is an integer from 1 to 4 inclusive,
- Rπ, R12 and Ri3, which may be identical or different independently of each other, are selected from hydrogen and (C1-C6)alkyl,
- Rι4 represents a group selected from (Cι-C6)alkyl, -Rι7-NRπRι2, -Rπ-NR, ι-C(=O)-R17-NR12R13, and -C(=O)O-Rι7-NRι 1R12 in which R17 represents a linear or branched (Cι-C6)alkylene group, and Rπ, R12 and R]3 are as defined hereinbefore,
- Rι5 represents a (C3-C6)cycloalkyl group,
- X5 represents a group selected from a single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C,-C6)alkyl,
- R16 represents a group selected from : a 5- or 6-membered monocyclic aryl or heteroaryl, which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (CrC6)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and - C(=O)OR7 wherein R7 represents hydrogen or (Cι-C6)alkyl, o and a 5- or 6-membered monocyclic cycloalkyl or heterocycloalkyl, which is optionally susbstituted by one or more groups, which may be identical or different 5 indepently of each other, selected from ( -C^alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR7 wherein R7 represents hydrogen or (Cι-C6)alkyl,
• m is an integer from 0 to 7 inclusive,
• the group(s) R2, which may be identical or different independently of each other, is (are) selected from (Cι-C6)alkyl, halogen, -CN, -NO2, -SCF3, -CF3, -OCF3, -NR7R8, -OR7,
[0 -SR7, -SOR7, -SO2R7, -(CH2)kSO2NR7R8, -X7(CH2)kC(=O)OR7, -(CH2)kC(=O)OR7, -X7(CH2)kC(=O)NR7R8, -(CH2)kC(=O)NR7R8, and -X8-Rι8 in which:
X represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (Cι-C6)alkyl,
- k is an integer from 0 to 3 inclusive,
L5 - R7 and R8, which may be identical or different independently of each other, are selected from hydrogen and (d-C6)alkyl,
- X8 represents a group selected from single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C C6)alkyl,
JO - Rι8 represents a group selected from phenyl, a 5- or 6-membered monocyclic, heteroaryl, and a 5- or 6-membered monocyclic cycloalkyl, each of these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (Cι-C6)alkyl, halogen, hydroxy and amino, and optionally, their racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts, and with the proviso that the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H- 1 ,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-l ,3-benzothiazine, 6- benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-l ,3-benzothiazine, 6-benzophenone-2,4-dioxo-
3,4-dihydro-2H-l,3-benzothiazine and 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4- dihydro-2H-l,3-benzothiazine.
According to a first embodiment, the invention relates to compounds of formula (I) wherein : • Gi represents a sulphur atom,
• G2 represents a group of formula (i/a):
/Y*X m
in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Yj represents an oxygen atom, and Y2 represents a group -NH, • Xι, X2, X , n, Zj, A, Re m and R2 are as defined in formula (I).
According to a second embodiment, the invention relates to compounds of formula (I) wherein :
• Gi represents an oxygen atom,
• G2 represents a group of formula (i/a):
/Y'X (i a) Y' in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Yi represents an oxygen atom, and Y2 represents a group -NH,
• Xi, X2, X3, n, Zi, A, Ri, m and R2 are as defined in formula (I).
According to a third embodiment, the invention relates to compounds of formula (I) wherein :
• Gi represents a sulphur atom, • G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xi, X2, X3, Zi, A, Rι; m and R2 are as defined in formula (I).
According to a fourth embodiment, the invention relates to compounds of formula (I) wherein :
• Gi represents an oxygen atom,
• G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xi, X2, X3, Zi, A, Ri, m and R2 are as defined in formula (I).
The substituent Ri that is preferred according to the invention is the group of formula (i/b):
Figure imgf000010_0001
wherein Z2, s, B, G3 and t are as defined in the compound of formula (I).
More particularly, the substituent Ri that is preferred according to the invention is the group of formula (i b):
Figure imgf000010_0002
wherein Z2 represents a group -CR Rι0 in which R9 and Rio represents each a hydrogen atom, s is equal to one, and B, G3, and t are as defined in the compound of formula (I).
More particularly, the substituent Ri that is preferred according to the invention is the group of formula (i/b):
Figure imgf000010_0003
wherein B represents a phenyl group, t is equal to 0 or 1, and G3, when it is present, represents a group selected from ORπ, halogen, and (CH2)kC(=O)ORι 1 in which Rπ represents an hydrogen atom or a (Cι-C6)alkyl group and k is equal to zero. Preferred compounds of the invention are compounds of formula (I) wherein X1; X2, and X represent each a group -CR3 in which R represents a hydrogen atom.
Other preferred compounds of the invention are compounds of formula (I) wherein X\ represents a group -CR3 in which R3 represents a hydrogen atom, X2 represents a nitrogen atom, and X3 represents a group -CR3 in which R3 represents a hydrogen atom.
Advantageously, preferred compounds of the invention are those compounds of formula (I) wherein Zi represents -CR4R5 in which t and R5 represent each a hydrogen atom, and n is equal to one.
Especially preferred compounds of the invention are compounds of formula (I) wherein A represents a phenyl group , m is equal to zero or one, and R2 represents a (C]-C6)alkoxy group or a hydrogen atom.
In another embodiment, preferred compounds of the invention are compounds of formula (I) wherein A represents a pyridyl group, m is equal to zero or one, and R2 represents a (Cι-C6)alkoxy group or a hydrogen atom.
Another especially preferred compounds of the invention are compound of formula (I) wherein A represents an imidazolyl group.
More particularly, the invention relates to the following compounds of formula (I) : - 3-benzyl-2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]thiazine-6-carboxylic acid 4-methoxy benzylamide;
3-(4-methoxybenzyl)2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]oxazine-6-carboxylic acid 4-methoxybenzylamide; - and 4-[2,4-dioxo-6-(3-phenyl-prop-l-ynyl)-4H-l,3-benzothiazin-3-ylmethyl]-benzoic acid.
The optical isomers, the N-oxides, as well as the addition salts with a pharmaceutically- acceptable acid or base, of the preferred compounds form an integral part of the invention. The invention also relates to a pharmaceutical composition comprising as active ingredient an effective amount of a compound of formula (I) together with one or more pharmaceutically-acceptable excipients or carriers.
Another embodiment of the invention concerns the use of the compound of formula (I) for the preparation of a medicinal product intended for treating a disease involving therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease.
The invention also relates to a method for treating a living body afflicted with a disease involving a therapy by inhibition of matrix metalloprotease, and more particularly of type- 13 matrix metalloprotease, the said method comprising the administration of an effective amount of a compound of formula (I) to a patient in need thereof.
A preferred method of treatment according to this invention is treatment of a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration and cancers.
More particularly, a preferred method of treatment according to this invention is treatment of disease selected from arthritis, osteoarthritis and rheumatoid arthritis.
DETAILED DESCRIPTION OF THE INVENTION
The compounds provided by this invention are those defined in formula (I). In formula (I), it is understood that :
- a (Cι-Cό)alkyl group denotes a linear or branched group containing from 1 to 6 carbon atoms ; example of such groups, without implying any limitation are methyl, ethyl, propyl, isopropyl, tert-butyl, neopentyl, hexyl, - a (C2-C6)alkenyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more double bonds ; examples of such groups without implying any limitation are vinyl, allyl, 3-buten-l-yl, 2-methyl-buten-l-yl, hexenyl, a (C2-C6)alkynyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more triple bonds ; examples of such groups without implying any limitation are ethynyl, propynyl, 3-butyn-l-yl, 2-methyl-butyn-l-yl, hexynyl, a (Cι-C6)alkoxy group means the alkyl group as mentioned above bound through an oxygen atom ; examples of such compounds without implying any limitation are methoxy, ethoxy, n-propyloxy, tert-butyloxy, - a mono(Cι-C6)alkylamino denotes a amino group substituted by one (Cι-C6)alkyl group as defined hereinbefore ; example of such groups, without implying any limitation are methyl amino, isobutyl amino, ethylamino, a di(Cι-C6)alkylamino denotes a amino group substituted by two (Cι-C6)alkyl groups as defined hereinbefore, each alkyl group being identical or different ; example of such groups, without implying any limitation are dimethylamino, diethylamino, an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated ; examples of such groups without implying any limitation are, phenyl, naphthyl, indenyl, benzocyclobutenyl, a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen ; examples of such groups without implying any limitation are furyl, thienyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzofuryl, benzothienyl, indolyl, quinolyl, isoquinolyl, imidazolyl, benzodioxolyl, benzodioxinyl, benzo[l,2,5]thiadiazolyl, benzo[ 1 ,2,5]oxadiazolyl, a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system being saturated or partially unsaturated but without aromatic character ; examples of such groups without implying any limitation are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, adamantyl, decalinyl, norbornyl, - a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen, a bicycle denotes two fused-monocycle or two bridged-monocycle, - a trihalogeno(Cι-C6)alkyl group denotes an alkyl group as defined above which contains a trihalogeno group ; examples of such groups without implying any limitation are trifluoromethyl, 2,2,2-trifluoroethyl,
- a (Cι-C7)acyl group denotes an alkyl group or an aryl group as defined above bound through a carbonyl group ; examples of such groups without implying any limitation are acetyl, ethylcarbonyl, benzoyl,
- a multiple bond denotes double bond or triple bond, a halogen atom means fluoro, chloro, bromo or iodo, optical isomers refer to racemates, enantiomers and diastereoisomers.
The invention also relates to the pharmaceutically acceptable salts of the compounds of formula (I). A review of the pharmaceutically acceptable salts will be found in J. Pharm.
Sci., 1977, 66, 1-19.
Pharmaceutically acceptable acids mean non-toxic mineral or organic acids. Among those there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, nitric acid, citric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid, benzoic acid, toluenesulfonic acid, etc...
Pharmaceutically acceptable bases mean non-toxic mineral or organic bases. Among those, there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, calcium hydroxide, triethylamine, tert-butylamine, dibenzylethylenediamine, piperidine, pyrrolidine, benzylamine, quaternary ammonium hydroxides etc...
The invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
Figure imgf000015_0001
in which Xj, X2, X3, and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO2alkyl,
compound of formula (II) which is treated in basic medium with an isocyanate compound of formula (III):
Figure imgf000015_0002
in which R\ has the same definitions as the compound of formula (I),
to yield the compound of formula (IV) :
Figure imgf000015_0003
in which X), X2, X3, Gls X, and Ri are as defined hereinbefore,
compound of formula (IV) in which the leaving group X is reacted with a cyanocuprate to yield the compound of formula (V) :
Figure imgf000015_0004
in which Xl5 X2, X3, Gj, and Ri are as defined hereinbefore,
which compound of formula (V) is treated with an acid like sulfuric acid to yield the compound of formula (VI):
Figure imgf000016_0001
in which Xi, X2, X , Gi, and Ri are as defined hereinbefore,
compound of formula (VI) which is treated with a compound of formula (VII):
Figure imgf000016_0002
in which Zi, R2, A, n and m have the same definitions as the compound of formula (I),
by activating the acid function with an activator, in the presence of diisopropylethylamine and a solvent, to yield the compound of formula (I/a) which is a particular case of the compounds of formula (I):
Figure imgf000016_0003
in which Xi, X2, X3, Gi, Z\, R\, R2, A, n and m are as defined hereinbefore,
compounds of formula (I a) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
The invention also relates to another process for the preparation of specific compounds of formula (I/a), which are a particular case of compounds of formula (I), which uses as starting material a compound of formula (11/ A):
Figure imgf000017_0001
in which G\ has the same definitions as the compound of formula (I),
compound of formula (II/A) which is treated with SOCl2 to yield the compound of formula (III/A) :
Figure imgf000017_0002
in which Gi is as defined hereinbefore,
compound of formula (III/A) reacting with a benzylamine derivative of formula (IV/A):
Figure imgf000017_0003
in which R2 and m are as defined in the compound of formula (I),
to yield the compound of formula (V/A):
Figure imgf000017_0004
in which Gi, m and R2 are as defined hereinbefore,
compound of formula (V/A) reacting with a chloroformate compound, to yield the compound of formula (I/c) which is a particular case of the compounds of formula (I):
Figure imgf000017_0005
in which Gi, R2 and m have the same definitions as the compound of formula (I), compounds of formula (I/c) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically- acceptable acid or base, or into N-oxide thereof.
The invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (II):
Figure imgf000018_0001
in which X2, X3, and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO2alkyl,
compound of formula (II) which is treated in basic medium with a benzylisocyanate to yield the compound of formula (VIII) :
Figure imgf000018_0002
in which Xi, X2, X3, Gi, and X are as defined hereinbefore,
compound of formula (VIII) which is treated with A1C13 in an apolar solvent to yield the compound of formula (IX) :
Figure imgf000018_0003
■0 in which Xi, X2, X3, Gi, and X are as defined hereinbefore, which compound of formula (IX) is treated in the presence of an inorganic base with a compound of formula (X):
Figure imgf000019_0001
in which R] is as defined in the compound of formula (I) and X' represents a leaving group like halogen atom, mesylate, tosyslate or triflate group,
to yield a compound of formula (XI) :
Figure imgf000019_0002
in which Xi, X2, X3, Gi, X and Ri are as defined hereinbefore,
compound of formula (XI) which is condensed, in the presence of dichlorobis(triphenylphosphine)palladium, cupper iodide and NN'-diisopropylethylamine in dimethylformamide, on a compound of formula (XII) :
Figure imgf000019_0003
in which Zi, R2, A, n and m have the same definitions as the compound of formula (I),
to yield the compound of formula (I/b), which is a particular case of the compound of formula (I):
Figure imgf000019_0004
in which Xi, X , X3, Gj, Z\,
Figure imgf000019_0005
R2, A, n and m are as defined hereinbefore,
compounds of formula (I/b) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically- acceptable acid or base, or into N-oxide thereof.
A general process for the synthesis of the compounds of formula (I) is described in the following scheme:
Figure imgf000020_0001
in which R is hydrogen or (Cι-C6)alkyl, R" is hydrogen or (Cι-C6)alkyl, and Rj, R2, G\,
X\, X2, X3, A, Yi, Zi, n and m have the same meaning as that defined for the compound of formula (I).
The compounds of the invention that are present in the form of a mixture of diastereoisomers are isolated in a pure form by using conventional separation techniques such as chromatography. As mentioned above, compounds of formula (I) of the present invention are matrix metalloprotease inhibitors, and more particularly inhibitors of the enzyme MMP-13.
In this respect, their use is recommended for the treatment of diseases or complaints involving a therapy by MMP-13 inhibition. By way of example, the use of the compounds of the present invention may be recommended for the treatment of any pathology in which destruction of extracellular matrix tissue occurs, and most particularly pathologies such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration and cancers.
The present invention also relates to pharmaceutical compositions comprising as active ingredient at least one compound of formula (I), an isomer thereof, a N-oxide thereof, or an addition salt thereof with a pharmaceutically-acceptable acid or base, alone or in combination with one or more pharmaceutically-acceptable, inert, non-toxic excipients or carriers.
Among the pharmaceutical compositions according to the invention, there may be mentioned more especially those that are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), per- or trans-cutaneous, intravaginal, rectal, nasal, perlingual, buccal, ocular or respiratory administration.
Pharmaceutical compositions according to the invention for parenteral injections especially include aqueous and non-aqueous sterile solutions, dispersions, suspension and emulsions, and also sterile powders for reconstituting injectable solutions or dispersions.
Pharmaceutical compositions according to the invention for oral administration in solid form especially include tablets or dragees, sublingual tablets, sachets, gelatin capsules and granules, for oral, nasal, buccal or ocular administration in liquid form, especially include emulsions, solutions, suspensions, drop, syrups and aerosols. Pharmaceutical compositions for rectal or vaginal administration are preferably suppositories, and those for per- or trans-cutaneous administration especially include powders, aerosols, creams, ointment, gels and patches.
The pharmaceutical compositions mentioned hereinbefore illustrate the invention but do 5 not limit it in any way.
Among the pharmaceutically acceptable, inert, non-toxic excipients or carriers there may be mentioned, by way of non-limiting example, diluents, solvents, preservatives, wetting agents, emulsifiers, dispersing agents, binders, swelling agents, disintegrating agents, retardants, lubricants, absorbents, suspending agents, colorants, aromatizing agents etc...
0 The useful dosage varies according to the age and weight of the patient, the administration route, the pharmaceutical composition used, the nature and severity of the disorder and the administration of any associated treatments. The dosage ranges from 2 mg to 1 g per day in one or more administrations. The compositions are prepared by methods that are common to those skilled in the art and generally comprise 0.5% to 60% by weight of active
5 principle (compound of formula (I)) and 40% to 99.5% by weight of pharmaceutically acceptable excipients or carriers.
The examples that follow illustrate the invention but do not limit it in any way.
The starting materials used are products that are known or that are prepared according to known operating procedures. The various preparations yield synthetic intermediates that '.0 are useful in preparation of the compounds of the invention. Some of these intermediates are new compounds.
The structures of the compounds described in the Examples and Preparations were determined according to the usual spectrophotometric techniques (infrared, nuclear magnetic resonance, mass spectrometry, ...) '5 In the Examples, it is understood that : - DMSO means dimethylsulfoxide,
- TOTU means O-(ethoxycarbonyl)cyanomethylamino]-N-N-N'-N'-tetramethyl uronium fluoroborate,
EXAMPLES
Intermediate A : 3-benzyl-6-bromo-3,4-dihydro-benzothiazine-2,4-dione
A stirred suspension of 5-bromo-2-mercaptobenzoic acid (prepared after K. Sindelar and coll., Coll. Czech. Chem. Comm, 1988, 53 (2), 340) (8 g, 34.3 mmol) in pyridine (100 ml) was treated with benzyl isocyanate (4.3 ml, 34.3 mmol) and the mixture was heated at 105°C for 7 hours under a nitrogen atmosphere. Further benzyl isocyanate was added (4.3 ml) and the mixture heated at 105°C overnight under stirring. After cooling to room temperature, water was added until precipitation and the suspension stirred for 1 hour. The resulting precipitate was collected by filtration, washed several times with water and dried under high vacuum to give 11.5g (yield : 96%) of the entitled compound as a white amorphous solid.
Intermediate B : 3-benzyl-6-cyano-3,4-dihydro-benzothiazine-2,4-dione
CuCΝ (0.197g, 2.2 mmol) was added to a suspension of 3-benzyl-6-bromo-3,4-dihydro- benzothiazine-2,4-dione (intermediate A ; 0.35 g, 1.22 mmol) in Ν-methylpyrrolidone (4 ml) and the suspension obtained was heated at reflux under stirring for 2.5 hours. The solvent was removed under reduced pressure and the sticky residue obtained was stirred in a mixture of ΝH4OH solution and dichloromethane. The organic phase was separated, washed with brine and dried over Na2SO4. The solvent was evaporated to afford 0.28 g of crude solid that was purified by chromatography on silica gel (cyclohexane 20/CH2Cl2 80) to give the entitled compound (0.15 g ; yield : 51%) as a white solid pure in TLC (cyclohexane 20 / CH2C1280 ; Rf = 0.40).
Intermediate C : 3-benzyl-6-carboxy-3,4-dihydro-benzothiazine-2,4-dione A suspension of 3-benzyl-6-cyano-3,4-dihydro-benzothiazine-2,4-dione (intermediate B ; 0.12 g, 0.4 mmol) in concentrated sulfuric acid (3 ml) and water (3 ml) was heated at reflux under stirring for 3 hours. After cooling to room temperature, water was added and the insoluble solid was collected by filtration, washed several times with water and dried under high vacuum to give, after purification by chromatography on silica gel (CH2C12
95/methanol 5), 0.04g (yield : 31%) of the entitled compound as a white solid pure in TLC (CH2C12 90 / methanol 10 ; Rf - 0.30).
Intermediate D : 4-hydroxy-N,N'-bis[(4-methoxyphenyl)methyl]-l,3- benzenedicarboxamide
A mixture of 4-hydroxyisophthalic acid (2.0 g ; 11 mmol) in thionyl chloride (20 ml) and dimethylformamide (2 drops) was heated at reflux under stirring overnight. The excess of thionyl chloride was removed by evaporation and the residue dissolved into dichloromethane (100 ml). After cooling, 4-methoxybenzylamine (6.8 g ; 50 mmol) was added in one portion and the mixture obtained was stirred at room temperature for 1 hour. The insoluble solid was separated by filtration and purified by chromatography on silica gel (CH2CI2 95/methanol 5) to give 2.0 g of the entitled compound (yield : 43%) as a white solid pure in TLC (CH2C12 90/methanol 10 ; Rf = 0.70).
Intermediate E : 6-bromo-3,4-dihydro-benzothiazine-2,4-dione
Under an inert atmosphere, aluminium chloride (5.51 g, 41.3 mmol) was added in portions to a suspension of 3-benzyl-6-bromo-3,4-dihydro-benzothiazine-2,4-dione (intermediate A ; 2.4 g, 6.89 mmol) in benzene (50 ml) and the mixture obtained was heated at 50°C under stirring for 2 hours. After cooling, the mixture was poured into iced water, the precipitated product was filtrated after 1 h standing, washed several times with water until neutral pH, dried and finally triturated in dichloromethane then dried under high vacuum to give 1.5 g (yield : 84%) of the entitled compound pure in TLC (CH2C12 ; Rf = 0.10). NMR H1 (DMSO) δ (ppm) : 5.5(s, 2H); 7.25-7.35 (m, 3H); 7.5 (m, 1H); 7.65 (m, 2H); 8.65 (m, 1H); 8.75 (m, 1H); 9.05 (s, 1H). Intermediate F : t-butyl 4-(6-bromo-2,4-dioxo-4 /-l,3-benzothiazin-3-ylmethyl)- benzoate
A suspension of 6-bromo-3,4-dihydro-benzothiazine-2,4-dione (intermediate E ; 1.5 g, 5.8 mmol) and cesium carbonate (1.89 g, 5.8 mmol) in dimethylformamide (20 ml) was stirred under a nitrogen atmosphere for 0.5 hour at room temperature and treated with 4-(t- butoxycarbonyl)benzyl bromide (1.57 g, 5.8 mmol) ; the mixture obtained was heated at 80°C under stirring and inert atmosphere for 2 hours. The solvent was removed under reduced pressure, and the residue was partitioned between water and dichloromethane. The aqueous layer was reextracted with CH2C12, the organic phases combined and dried over Na2SO . The solvent was removed under reduced pressure to afford 2.4 g of crude solid that was purified by chromatography on silica gel (CH2CI2) to give the entitled compound (1.95 g ; yield : 85%) as a white solid pure in TLC (CH2C1299/CH3OH 1 ; Rf = 0.70).
Intermediate G : 4-(6-bromo-2,4-dioxo-4H-l,3-benzothiazin-3-ylmethyl)-benzoic acid
A stirred solution of 6-bromo-3-(4-t-butoxycarbonylbenzyl)-3,4-dihydro-benzothiazine-
2,4-dione (intermediate F ; 0.6 g, 1.34 mmol) in CH2CI2 (60 ml) was treated at room temperature with trifluoroacetic acid (6 ml). The reaction mixture was stirred overnight at room temperature and poured into water; the resulting insoluble product was isolated by filtration, washed several times until neutral pH and dried under vacuum to afford the entitled acid (0.45 g ; yield : 86%) as a white solid pure in TLC (CH2C12 95/CH3OH 5 ; Rf
= 0.35).
Example 1 : 3-BenzyI-2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]thiazine-6-carboxylic acid 4-methoxy benzylamide
Figure imgf000025_0001
To a solution of 25 mg (0.08 mmol) of intermediate C in 2 ml of dimethylformamide, 10.9 mg (0.08 mmol) of 4-methoxybenzylamine and 26 mg (0.08 mmol) of TOTU were added under stirring. After external cooling with ice bath, 20 mg (0.16 mmol) of N,N- diisopropyl-N-ethylamine were added and the yellow resulting solution was stirred overnight at room temperature. The solvent was removed under vacuum and the residual brown oil was purified by column chromatography over silica gel (dichloromethane then dichloromethane / methanol : 99.5 / 0.5) to yield 13 mg of the desired product (yield : 38%).
N.M.R (CDC13) Η δ (ppm) : 3.8 (s, 3H) ; 4.6 (d, 2H) ; 5.35 (s, 2H) ; 6.5 (s, 1H) ; 6.9 (d, 2H) ; 7.2-7.35 (m, 5H) ; 7.4 (d, 2H) ; 7.5 (d, 2H) ; 8.15 (d, 1H) ; 8.6 (s, 1H). IR : 1649, 1543, 1514, 1406, 1284, 1253, 1231, 1 185, 1145, 1030, 824, 731 cm"1 HPLC : Purity = 96%
Example 2 : 3-Benzyl-2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]oxazine-6-carboxylic acid 4-methoxy benzylamide
Figure imgf000026_0001
A cooled solution of N, N'-bis-(4-methoxybenzyl)-4-hydroxyisophthalic acid (intermediate D, 0.42 g, 1 mmol) in pyridine (5 ml) and acetonitrile (3 ml) was treated with ethyl chloroformate (0.12 g, 1.1 mmol) under stirring and the mixture was heated at 120°C for 8 hours under a nitrogen atmosphere. Further ethyl chloroformate was added (1.1 ml) and the mixture heated at 120°C overnight under stirring. After cooling to room temperature, the reaction mixture was poured into diluted hydrochloric solution and the product extracted several times with dichloromethane. The joined organic phases were washed with diluted hydrochloric solution, diluted solution of sodium hydroxide and brine successively and dried over Na2SO4. The solvent was evaporated and the residue triturated in dichloromethane; the insoluble solid is filtrated and dried to afford the entitled compound (0.32 g ; yield : 71%) as a white solid pure in TLC (CH2C1295/methanol ; Rf = 0.40). N.M.R (DMSO- Η δ (ppm) : 3.7 (s, 6H); 4.4 (d, 2H); 6.8-6.9 (m, 4H); 7.25 (d, 2H); 7.3 (d, 2H); 7.5 (d, 1H); 8.25 (d, 1H); 8.5 (s, 1H); 9.25 (t, 1H). IR : 1759, 1693, 1638, 1513, 1446, 1327, 1305, 1244 cm"1
MP = 157°C
HPLC : Purity - 98.5%
Example 3 : 4-[2,4-Dioxo-6-(3-phenyl-prop- -ynyl)-4H-l,3-benzotb.iazm-3- ylmethylj-benzoic acid
Figure imgf000027_0001
6-bromo-3-(4-carboxybenzyl)-3,4-dihydro-benzothiazine-2,4-dione (Intermediate G) (0.39 g ; 0.994 mmol) in dimethylformamide (4 ml) was stirred at room temperature under nitrogen atmosphere and N-ethyl-N,N-diisopropylamine (0.51 g, 3.97 mmol) was added ; the mixture was stirred until complete solubilisation. At this time, 3-phenylprop-l-yne (0.16 g ; 1.39 mmol) was added followed by PdCi2(PPh3)2 (30 mg) and a catalytic amount of Cul. The mixture obtained was heated to 50°C under nitrogen atmosphere and maintained under stirring for 3 hours. After cooling, the solvent was removed under reduced pressure and the semi-solid residue obtained was stirred in a mixture of water and dichloromethane for 25 minutes. The solid insoluble in the 2 phases was isolated by filtration, washed with CH2CI2 and dried under vacuum to afford a first portion (0.16 g) of the entitled compound. The organic phase was separated, washed with brine, dried over Na2SO4 and evaporated to give an additional portion (0.23 g) of the desired compound (yield 92%).
N.M.R (DMSO-d6) 1H δ (ppm) : 3.94 (s, 2H); 5.23 (s, 2H); 7.27 (t, 1H); 7.37 (t, 2H); 7.40- 7.50 (m, 4H); 7.67 (d, 1H); 7.84-7.95 (m, 2H); 8.23 (s, 1H); 12.75-13.05 (m, 1H). IR : 1690, 1638, 1425, 1408, 1341, 1318, 1297, 1286, 1181, 1149, 913, 768, 726, 707 cm"1 MP = 240-242°C HPLC : Purity = 98%
PHARMACOLOGICAL STUDIES OF COMPOUNDS OF THE INVENTION Example 4 : Evaluation of the in vitro activity of the MMP-13 inhibitor compounds according to the invention.
The inhibitory activity of the compounds of formula (I) according to the invention with respect to matrix metalloprotease-13 is evaluated by testing the ability of the compounds of the invention to inhibit the proteolysis of a peptide substrate with MMP- 13.
The peptide substrate used in the test is the following peptide: Ac-Pro-Leu-Gly-thioester-
Leu-Leu-Gly-OEt.
The inhibitory activity of a compound of formula (I) according to the invention is expressed as the IC50 value, which is the concentration of inhibitor for which an inhibition of 50%) of the activity of the matrix metalloprotease under consideration is observed.
To carry out this test, a reaction medium of 100 μl volume is prepared, containing: 50 mM of HEPES buffer, 10 mM of CaCl2 and 1 mM of 5,5'-dithiobis-(2-nitrobenzoic acid)
(DTNB), and 100 μM of substrate, the pH being adjusted to 7.0.
Increasing concentrations of the inhibitory compound present in a 2.0%> DMSO solution and 2.5 nM of the catalytic domain of human MMP-13 are added to the test samples.
The concentrations of inhibitors present in the test samples range from 100 μM to 0.5 nM.
The measurement of the proteolysis of the substrate peptide is monitored by measuring the absorbance at 405 nm using a spectrophotometer for reading microplates, at the laboratory temperature, the measurements being carried out continuously for 10 to 15 minutes. The IC50 values are calculated from a curve in which the percentage of the catalytic activity relative to the control is represented on the X-axis and the concentration of inhibitor is represented on the Y-axis.
The IC50 values on MMP-13 of the compounds of Examples 1, 2 and 3 are respectively
0.037μM, 0.063μM, and 0.0012μM.
The test described above for the inhibition of MMP-13 was also adapted and used to determine the ability of the compounds of formula (I) to inhibit the matrix metalloproteases MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14. The results obtained show that the compounds according to the invention generally have IC50 values for MMP-13 which are about 100 times lower than the IC50 values for the same compounds with respect to the other matrix metalloproteases tested. Then the IC50 values on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP- 12 and MMP- 14 for the compound of Example 1 are respectively 30μM, lOOμM, 18μM, 30μM, lOOμM, lOOμM, and lOOμM.

Claims

1 - A compound selected from those of formula (I):
Figure imgf000030_0001
wherein: • Xi, X2, and X3, independently of each other, represent a nitrogen atom or a group -CR3 in which R3 represents a group selected from hydrogen, (Cι-C6)alkyl, amino, mono(Cι-C6)alkylamino, di(Cι-C6)alkylamino, hydroxy, (Cι-C6)alkoxy, and halogen, it being understood that not more than two of the groups X1} X2 and X3 simultaneously represent a nitrogen atom,
• Gi represents an oxygen atom or a group S(O)p in which p represents an integer from 0 to 2 inclusive,
• G2 represents a group selected from carbon-carbon triple bond, C=O, C=S, S(O)q in which q represents an integer from 0 to 2 inclusive, or a group of formula (i/a):
/YjX (l/a)
in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Y\ represents a group selected from oxygen, sulphur, -NH and -N(Cj-C6)alkyl, and Y2 represents a group selected from oxygen, sulphur, -NH and -N(Cι-C6)alkyl,
• n represents an integer from 0 to 6 inclusive,
• Zj represents -CRιR5ι wherein R4 and R5> identical or different independently of each other, represent a group selected from hydrogen, (Cι-C6)alkyl, trihalogeno(Cι-C6)alkyl, halogen, amino, mono(Cι-C6)alkylamino, di(Cι-C6)alkylamino in which each alkyl moiety is identical or different, -ORδ, -SRό, and -C(=O)OR , in which R^ is hydrogen atom or (Cι-C6)alkyl, and
- wherein when n is greater than or equal to 2, the hydrocarbon chain Z\ optionally contains one to two isolated or conjugated multiple bonds, - and/or wherein when n is greater than or equal to 2 one of said -CR4R5 may be replaced with a group selected from oxygen, S(O)r in which r represents an integer from 0 to 2 inclusive, -NH and -N(Cι-C6)alkyl,
• A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
• Ri represents a group selected from : hydrogen, - (Cι-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(Cι-Cό)alkyl, cycloalkyl, -C(=O)NR7R8, -C(=O)OR7, OR7, and SR7, in which R7 and R8, which may be identical or different independently of each other, represent hydrogen or (C1-C6)alkyl, and the group of formula (i/b) :
Figure imgf000031_0001
in which s is an integer from 0 to 8 inclusive,
■f Z2 represents -CR9Rιo wherein R9 and Rι0, identical or different independently of each other, represent a group selected from hydrogen, (Cι-C6)alkyl, phenyl, trihalogeno(Cι-C6)alkyl, halogen, amino, ORό, SRό and -C(=O)ORό in which R is as defined hereinbefore, and
- wherein when s is greater than or equal to 2, the hydrocarbon chain Z2 optionally contains one or two isolated or conjugated multiple bonds, - and/or wherein when p is greater or equal to 2, one of said -CR R10 may be replaced with a group selected from oxygen, S(O)u in which u is an integer from 0 to 2 inclusive, -NH, -N(Cι-C6)alkyl, and carbonyl,
B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being a 5- or 6-membered monocycle, or bicycle itself composed of two 5- or 6-membered monocycles,
■S t is an integer from 0 to 7 inclusive,
■S the group(s) G3, which may be identical or different independently of each other, is (are) selected from (Cι-C6)alkyl, halogen, CN, NO2, CF3, OCF3, -(CH2)kNRuRi2, -N(R, ,)C(=O)R12, -N(R, ,)C(=O)OR,2, -N(Rπ)SO2R,2, -N(SO2R, ,)2, -OR, , , -S(O)klR„, -SO2-N(R„)-(CH2)k2- R,2Ri3, -(CH2)kSO2NRnRi2,
Figure imgf000032_0001
-C(=O)O-(CH2)k2-C(=O)OR14, -X4(CH2)kC(=O)NRι ιR12, -(CH2)kC(=O) R, ,R12,
-R15-C(=O)ORπ, -X5-R16, and -C(=O)-Rι7-NRuRι2 in which :
- X4 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by a hydrogen or a (Cι-C6)alkyl group,
k is an integer from 0 to 3 inclusive,
kl is an integer from 0 to 2 inclusive,
k2 is an integer from 1 to 4 inclusive,
Rπ, Rι2 and R]3, which may be identical or different independently of each other, are selected from hydrogen and (Cι-C6)alkyl,
- R)4 represents a group selected from (Cι-C6)alkyl, -R17-NRπR]2,
Figure imgf000032_0002
in which R17 represents a a linear or branched (Cι-C6)alkylene group, and Rπ, Rι2 and R13 are as defined hereinbefore,
- R15 represents a (C3-C6)cycloalkyl group,
X5 represents a group selected from a single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (Cι-C6)alkyl,
Rι6 represents a group selected from : o a 5- or 6-membered monocyclic aryl or heteroaryl, which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (Cι-C6)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and - C(=O)OR7 wherein R7 represents hydrogen or (Cι-C6)alkyl, o and a 5- or 6-membered monocyclic cycloalkyl or heterocycloalkyl, which is optionally susbstituted by one or more groups, which may be identical or different indepently of each other, selected from (Cι-C6)alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR7 wherein R7 represents hydrogen or (Cι-C6)alkyl,
• m is an integer from 0 to 7 inclusive,
• the group(s) R2, which may be identical or different independently of each other, is (are) selected from (Cι-C6)alkyl, halogen, -CN, -NO2, -SCF3, -CF3, -OCF3, -NR7R8, -OR7, -SR7, -SOR7, -SO2R7, -(CH2)kSO2NR7R8, -X7(CH2)kC(=O)OR7, -(CH2)kC(=O)OR7, -X7(CH2)kC(=O)NR7R8, -(CH2)kC(=O)NR7R8, and -X8-Rι8 in which:
- X7 represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (Cι-C6)alkyl,
- k is an integer from 0 to 3 inclusive,
- R7 and R8, which may be identical or different independently of each other, are selected from hydrogen and (Cι-C6)alkyl, X8 represents a group selected from single bond, -CH2-, oxygen, sulphur optionally substituted by one or two oxygen, and nitrogen substituted by hydrogen or (C,-C6)alkyl,
Rι8 represents a group selected from phenyl, a 5- or 6-membered monocyclic, 5 heteroaryl, and a 5- or 6-membered monocyclic cycloalkyl, each of these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (Cι-C6)alkyl, halogen, hydroxy and amino,
and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable 10 salts, it being understood that : an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially [5 hydrogenated ; a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen ; a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, these systems being saturated or partially unsaturated but without aromatic >0 character ;
- a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen, and a bicycle denotes two fused-monocycle;
15 and with the proviso that the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H-
1 ,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-l ,3-benzothiazine, 6- benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-1.3-benzothiazine, 6-benzophenone-2,4-dioxo- 3,4-dihydro-2H- 1 ,3-benzothiazine and 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4- dihydro-2H-l,3-benzothiazine.
2- A compound according to claim 1 wherein :
• Gi represents a sulphur atom, • G2 represents a group of formula (i/a):
^'f (i/a)
V, in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Yi represents an oxygen atom, and Y2 represents a group -NH,
• Xi, X2, X3, n, Zi, A, Ri, m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
3- A compound according to claim 1 wherein :
• Gi represents an oxygen atom,
• G2 represents a group of formula (i/a):
Figure imgf000035_0001
in which the carbon atom with the number 1 is attached to the bicycle of the compound of formula (I), Yi represents an oxygen atom, and Y2 represents a group -NH,
• Xi, X2, X3, n, Z\, A, R], m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
4- A compound according to claim 1 wherein :
• Gi represents a sulphur atom,
• G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive, Xi, X2, X , Zi, A, Ri, m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
5- A compound according to claim 1 wherein :
• Gi represents an oxygen atom, • G2 represents a carbon-carbon triple bond,
• n represents an integer from 1 to 6 inclusive,
Xi, X2, X3, Z\, A, Rj, m and R2 are as defined in formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
6- A compound according to claim 1 wherein Rj represents a group of formula (i/b):
Figure imgf000036_0001
wherein Z2, s, B, G and t are as defined in the compound of formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
7- A compound according to claim 6 wherein Ri represents a group of formula (i/b):
Figure imgf000036_0002
wherein Z2 represents a group -CR9Rιo in which R9 and Rι0 represents each a hydrogen atom, s is equal to one, and B, G3, and t are as defined in the compound of formula (I), and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
8- A compound according to claim 7 wherein Ri represents a group of formula (i/b):
Figure imgf000036_0003
wherein B represents a phenyl group, t is equal to 0 or 1, and G3, when it is present, represents a group selected from ORπ, halogen, and (CH2)kC(=O)ORπ in which Rπ represents an hydrogen atom or a (C]-C6)alkyl group and k is equal to zero, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
9- A compound according to claim 1 wherein X1 } X2, and X3 represent each a group -CR3 in which R3 represents a hydrogen atom, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
10- A compound according to claim 1 wherein Xi represents a group -CR3 in which R3 represents a hydrogen atom, X2 represents a nitrogen atom or a group -CR3 in which R3 represents a hydrogen atom, and X3 represents a group -CR3 in which R3 represents a hydrogen atom, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
11- A compound according to claim 1 wherein Zi represents -CR-tR5 in which R and R5 represent each a hydrogen atom, and n is equal to one, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
12- A compound according to claim 1 wherein A represents a phenyl group, m is equal to zero or one, and R2 represents a (Cι-C6)alkoxy group or a hydrogen atom, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
13- A compound according to claim 1 wherein A represents a pyridyl group, m is equal to zero or one, and R2 represents a (Cι-C6)alkoxy group or a hydrogen atom, and optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
14- A compound according to claim 1 wherein A represents an imidazolyl group, optionally, its racemic forms, isomers, N-oxides, and pharmaceutically acceptable salts.
15- A compound according to claim 1 selected from:
- 3-benzyl-2,4-dioxo-3,4-dihydro-2H-benzo[e][l,3]thiazine-6-carboxylic acid 4-methoxy benzylamide; - 3-(4-methoxybenzyl)2,4-dioxo-3,4-dihydro-2H-benzo[e] [ 1 ,3]oxazine-6-carboxylic acid 4-methoxybenzylamide; and 4-[2,4-dioxo-6-(3-phenyl-prop- 1 -ynyl)-4H- 1 ,3-benzothiazin-3-ylmethyl]-benzoic acid.
16- A process for the preparation of compounds according to claim 1 in which uses as starting material a compound of formula (II):
Figure imgf000038_0001
in which Xi, X2, X3, and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO2alkyl,
compound of formula (II) which is treated in basic medium with an isocyanate compound of formula (III):
RrNCO (III) in which R! has the same definitions as the compound of formula (I),
to yield the compound of formula (IV) :
Figure imgf000038_0002
in which Xl5 X2, X3, Gl s X, and Ri are as defined hereinbefore,
compound of formula (IV) in which the leaving group X is reacted with a cyanocuprate to yield the compound of formula (V) :
Figure imgf000039_0001
in which Xl s X2, X3, Gi, and Ri are as defined hereinbefore,
which compound of formula (V) is treated with an acid like sulfuric acid to yield the compound of formula (VI):
Figure imgf000039_0002
in which Xi, X2, X3, Gls and Ri are as defined hereinbefore,
compound of formula (VI) which is treated with a compound of formula (VII):
Figure imgf000039_0003
in which Z1; R2, A, n and m have the same definitions as the compound of formula (I),
by activating the acid function with an activator, in the presence of diisopropylethylamine and a solvent, to yield the compound of formula (I/a) which is a particular case of the compounds of formula (I):
Figure imgf000039_0004
in which X\, X2, X3, G\, Z\, R\, R2, A, n and m are as defined hereinbefore,
compounds of formula (I/a) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
17- A process for the preparation of compounds according to claim 1 in which uses as starting material a compound of formula (II):
Figure imgf000040_0001
in which Xls X2, X3, and Gi have the same definitions as the compound of formula (I), and X represents a leaving group selected from halogen, triflate, mesyslate, tosylate and SO2alkyl,
compound of formula (II) which is treated in basic medium with a benzylisocyanate to yield the compound of formula (VIII) :
Figure imgf000040_0002
in which Xi, X2, X3, Gi, and X are as defined hereinbefore,
compound of formula (VIII) which is treated with A1C1 in an apolar solvent to yield the compound of formula (IX) :
Figure imgf000040_0003
in which X1; X2, X , Gi, and X are as defined hereinbefore,
which compound of formula (IX) is treated in the presence of an inorganic base with a compound of formula (X):
R,-X' (X) in which Ri is as defined in the compound of formula (I) and X' represents a leaving group like halogen atom, mesylate, tosyslate or triflate group,
to yield a compound of formula (XI) :
Figure imgf000041_0001
in which Xi, X2, X3, Gi, X and Ri are as defined hereinbefore,
compound of formula (XI) which is condensed, in the presence of dichlorobis(triphenylphosphine)palladiurn, cupper iodide and NN '-diisopropylethylamine in dimethylformamide, on a compound of formula (XII) :
Figure imgf000041_0002
in which Zi, R2, A, n and m have the same definitions as the compound of formula (I),
to yield the compound of formula (I/b), which is a particular case of the compound of formula (I):
Figure imgf000041_0003
in which Xi, X2, X3, Gi, Z\, Ri, R2, A, n and m are as defined hereinbefore,
compounds of formula (I/b) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into Ν-oxide thereof. 18 - A process for the preparation of compounds according to claim 1 in which uses as starting material a compound of formula (II/A):
Figure imgf000042_0001
in which Gi has the same definitions as the compound of formula (I),
compound of formula (I A) which is treated with SOCI2 to yield the compound of formula (III/A) :
Figure imgf000042_0002
in which Gi is as defined hereinbefore,
compound of formula (III/A) reacting with a benzylamine derivative of formula (IV/A):
Figure imgf000042_0003
in which R2 and m are as defined in the compound of formula (I),
to yield the compound of formula (V/A):
Figure imgf000042_0004
in which Gi, m and R2 are as defined hereinbefore,
compound of formula (V/A) reacting with a chloroformate compound, to yield the compound of formula (I/c) which is a particular case of the compounds of formula (I):
Figure imgf000043_0001
in which G\, R2 and m have the same definitions as the compound of formula (I), compounds of formula (I/c) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.
19- A method for treating a living body afflicted with a disease where the inhibition of type -13 matrix metalloprotease is involved, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said conditions.
20- A method for treating a living body afflicted with a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said conditions.
21- A pharmaceutical composition comprising as active ingredient an effective amount of a compound as claimed in claim 1, alone or in combination with one or more pharmaceutically-acceptable excipients or carriers.
22- A pharmaceutical composition useful in the method of Claim 19 comprising as active ingredient an effective amount of a compound as claimed in claim 1, together with one or more pharmaceutically-acceptable excipients or carriers. 23- A pharmaceutical composition useful in the method of Claim 19 comprising as active ingredient an effective amount of a compound as claimed in claim 2, together with one or more pharmaceutically-acceptable excipients or carriers.
24- A pharmaceutical composition useful in the method of Claim 19 comprising as active ingredient an effective amount of a compound as claimed in claim 4, together with one or more pharmaceutically-acceptable excipients or carriers.
25- Use of a compound according to Claim 1, for the preparation of a medicinal product intended for treating a disease involving therapy by inhibition of type- 13 matrix metalloproteases.
26- Use according to Claim 25, characterized in that the disease is arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers.
27- Use according to Claim 26, characterized in that the disease is arthritis.
28- Use according to Claim 26, characterized in that the disease is osteoarthritis.
29- Use according to Claim 26, characterized in that the disease is rheumatoid arthritis.
PCT/EP2003/006601 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis WO2004000322A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003246574A AU2003246574A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
MXPA05000004A MXPA05000004A (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis.
BR0312107-0A BR0312107A (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for the treatment of arthritis
CA002491210A CA2491210A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
EP03760686A EP1539176A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
JP2004514844A JP2005538965A (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as MMP-13 inhibitors for the treatment of arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/008062 WO2004000321A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
EPPCT/EP/02/08062 2002-06-25

Publications (1)

Publication Number Publication Date
WO2004000322A1 true WO2004000322A1 (en) 2003-12-31

Family

ID=29797117

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2002/008062 WO2004000321A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
PCT/EP2003/006601 WO2004000322A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008062 WO2004000321A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Country Status (6)

Country Link
JP (1) JP2005538965A (en)
AU (2) AU2002333256A1 (en)
BR (1) BR0312107A (en)
CA (1) CA2491210A1 (en)
MX (1) MXPA05000004A (en)
WO (2) WO2004000321A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828326B2 (en) 2002-08-13 2004-12-07 Warner-Lambert Company Pyrimidinone fused bicyclic metalloproteinase inhibitors
US6849637B2 (en) 2001-02-14 2005-02-01 Warner-Lambert Company Triazolo compounds as MMP inhibitors
US6869958B2 (en) 2002-08-13 2005-03-22 Warner-Lambert Company Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6908917B2 (en) 2002-08-13 2005-06-21 Warner-Lambert Company Chromone derivatives as matrix metalloproteinase inhibitors
US6949651B2 (en) 2002-08-13 2005-09-27 Warner-Lambert Company Fused bicyclic metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6977261B2 (en) 2002-08-13 2005-12-20 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
US7132424B2 (en) 2002-08-13 2006-11-07 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
US7160893B2 (en) 2002-08-13 2007-01-09 Warner-Lambert Company Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
US7179822B2 (en) 2002-08-13 2007-02-20 Warner-Lambert Company Hetero biaryl derivatives as matrix metalloproteinase inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112159347B (en) * 2020-10-27 2022-06-07 常州工程职业技术学院 Preparation method of picolitamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140532A (en) * 1976-12-17 1979-02-20 Fuji Photo Film Co., Ltd. Thermally developable light-sensitive material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140532A (en) * 1976-12-17 1979-02-20 Fuji Photo Film Co., Ltd. Thermally developable light-sensitive material

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOLLET ET AL.: "Solid-phase synthesis of alpha-substituted 3-bisarylthio N-hydroxy propionamides as specific MMP inhibitors", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 10, no. 3, 2002, pages 531 - 544, XP002224266 *
MONTANA J ET AL: "THE DESIGN OF SELECTIVE NON-SUBSTRATE-BASED MATRIX METALLOPROTEINASE INHIBITORS", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 3, 2000, pages 353 - 361, XP000984034, ISSN: 1367-6733 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849637B2 (en) 2001-02-14 2005-02-01 Warner-Lambert Company Triazolo compounds as MMP inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6828326B2 (en) 2002-08-13 2004-12-07 Warner-Lambert Company Pyrimidinone fused bicyclic metalloproteinase inhibitors
US6869958B2 (en) 2002-08-13 2005-03-22 Warner-Lambert Company Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
US6908917B2 (en) 2002-08-13 2005-06-21 Warner-Lambert Company Chromone derivatives as matrix metalloproteinase inhibitors
US6949651B2 (en) 2002-08-13 2005-09-27 Warner-Lambert Company Fused bicyclic metalloproteinase inhibitors
US6977261B2 (en) 2002-08-13 2005-12-20 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
US7132424B2 (en) 2002-08-13 2006-11-07 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
US7160893B2 (en) 2002-08-13 2007-01-09 Warner-Lambert Company Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
US7179822B2 (en) 2002-08-13 2007-02-20 Warner-Lambert Company Hetero biaryl derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
MXPA05000004A (en) 2005-04-08
JP2005538965A (en) 2005-12-22
CA2491210A1 (en) 2003-12-31
AU2003246574A1 (en) 2004-01-06
BR0312107A (en) 2005-03-29
AU2002333256A1 (en) 2004-01-06
WO2004000321A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
US20040006077A1 (en) Thiazine and oxazine derivatives as MMP-13 inhibitors
EP0471236B1 (en) Imidazopyridine derivatives and their use
AU601484B2 (en) Imidazopyridine derivatives
US20030216402A1 (en) Oxo-azabicyclic compounds
EP0873329B1 (en) Novel n-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
US6747147B2 (en) Oxo-azabicyclic compounds
US20030130278A1 (en) Alkynylated fused ring pyrimidine compounds
HUT60462A (en) Process for producing biphenyl derivatives and pharmaceutical compositions comprising same
WO2004000322A1 (en) Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
JP2005526070A (en) Oxo-azabicyclic compounds
KR100514201B1 (en) Piperidine Derivatives with PF Antagonist Activity
JPH10510536A (en) 2-Substituted 1,2,5-thiadiazolidine-3-one 1,1-dioxides and compositions thereof
JPS60226866A (en) 1,5-benzothiazepine derivative and its preparation
US3417085A (en) 3,1-benzothiazines and 3,1-benzoxazines
EP0233762A2 (en) Use of aromatic diamines for the treatment of angina pectoris, and diamines therefor
AU2004276128B2 (en) Amide-type carboxamide derivatives
GB2217709A (en) Anti-tumour 4-oxoquinazolines
KR100251522B1 (en) Pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group and pharmaceutically acceptable salts thereof
PL154813B1 (en) Method of obtaining s enantiomeric derivatives of glutar amide
EP1539176A1 (en) Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
JP2003212837A (en) Amidine derivative, anticoagulant agent given by using the same, and remedy for thrombosis
JPH04221380A (en) Benzoxazine derivative, preparation thereof and use thereof for curing and preventing disease
JP2517582B2 (en) Pyrrolidone derivative and its use
WO2003033477A1 (en) Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
EP0702952B1 (en) Benzopyran derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003760686

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/A/2005/000004

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2491210

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004514844

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003760686

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003760686

Country of ref document: EP